Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Redhill Biopharma Ltd
RDHLCurrent price
9.75 USD
-0.4 USD (-3.94%)
Last closed
10.34 USD
Company
www.redhillbio.com
ISIN
US7574681034
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
Capitalization
14 098 746 USD
Yield for 12 month
-98.05 %
1Y
3Y
5Y
10Y
15Y
RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Address: 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
19 000 USDP/E ratio
–Dividend Yield
–Current Year
+6 513 173 USD
Last Year
+61 800 000 USD
Current Quarter
+1 796 000 USD
Last Quarter
+12 798 000 USD
Current Year
+3 063 087 USD
Last Year
+28 463 000 USD
Current Quarter
+990 000 USD
Last Quarter
+4 200 000 USD
Key Figures RDHL
1 year
3 years
5 years
10 years
EBITDA
-20 941 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-44.88 %
PEG Ratio
–
Return On Equity TTM
-1708.61 %
Wall Street Target Price
19 000 USD
Revenue TTM
3 707 000 USD
Book Value
0.052 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-28.4 %
Dividend Yield
–
Gross Profit TTM
45 251 000 USD
Earnings per share
-302.63 USD
Diluted Eps TTM
-302.63 USD
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RDHL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RDHL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:25
Payout Ratio
–
Last Split Date
20.08.2024
Dividend Date
–
Stock Valuation RDHL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
1428.5714
Enterprise Value Revenue
1.9908
Price Sales TTM
3.8033
Enterprise Value EBITDA
0.3005
Price Book MRQ
231.1268
Financials RDHL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RDHL
For 52 weeks
6.43 USD
82 USD
50 Day MA
9.94 USD
Shares Short Prior Month
541 459
200 Day MA
15.92 USD
Short Ratio
0.15
Shares Short
120 468
Short Percent
10.62 %
BeatStart